Danaher Corporation has been recommended as a Buy by UBS due to its strong focus on two primary product families.

The company generates 70.1% of its net sales from medical devices, including diagnostic equipment, digital imaging systems, optical instruments, and consumables.

The remaining 29.9% of sales come from professional analytical instruments, such as water quality control systems and disinfection products.

Geographically, Danaher’s net sales are diversified, with 40.1% coming from the United States, 13.2% from China, and the remaining 46.7% from other international markets.

This broad distribution highlights the company's strong market presence and growth potential across various regions.